PLAINSBORO, N.J.--(BUSINESS WIRE)--June 1, 2001--Integra LifeSciences Holdings Corporation (NASDAQ:IART) today announced that it has filed a shelf registration statement on Form S-3 with the Securities and Exchange Commission.
When effective, the registration statement will permit Integra to offer and sell various types of securities, from time to time, up to an aggregate value of $75 million. Integra filed the registration statement to gain additional flexibility in accessing capital markets for general corporate purposes, which could include, among other things, acquisition of product lines or companies, repayment of indebtedness, or the expansion of sales and marketing.
The registration statement has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time that the registration statement becomes effective. '
This news release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification of the securities under the securities laws of that state. Integra has no current plans to sell any of the securities covered by the registration statement.
Integra LifeSciences Holdings Corporation develops, manufactures and markets medical devices, implants and biomaterials primarily used in the treatment of cranial and spinal disorders, soft tissue repair and orthopedics. Integra is a leader in applying the principles of biotechnology to medical devices that improve patients' quality of life.
The Company has its corporate headquarters in Plainsboro, New Jersey, with manufacturing and research facilities located throughout the world. The Company has approximately 550 permanent employees. Please visit the Company's website at www.integra-ls.com.
This news release and the registration statement to which it refers contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking factors in this news release include, but are not limited to, statements concerning the use of proceeds generated from the sale of Integra's securities.
Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, changes in the Company's financing needs may affect the use of proceeds generated from the sale of Integra's securities.
In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" in the registration statement and in the Business section of Integra's Annual Report on Form 10-K/A for the year ended December 31, 2000 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
|Source:||Integra LifeSciences Holdings Corporation|
|CONTACT:||Integra LifeSciences Holdings Corporation|
|John B. Henneman, III, 609/936-2481|
|John Bostjancic, 609/936-2239|